SEARCH

SEARCH BY CITATION

References

  • 1
    Hanniffy S, Wiedermann U, Repa A, Mercenier A, Daniel C, Fioramonti J, et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004;56:164.
  • 2
    Kumar A, Teuber SS, Gershwin ME. Why do people die of anaphylaxis? A clinical review. Clin Dev Immunol 2005;12:281287.
  • 3
    Akbari O, Stock P, DeKruyff RH, Umetsu DT. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 2003;15:627633.
  • 4
    Thorstenson KM, Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 2001;167:188195.
  • 5
    Prescott SL, Dunstan JA. Immune dysregulation in allergic respiratory disease: the role of T regulatory cells. Pulm Pharmacol Ther 2005;18:217228.
  • 6
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608615.
  • 7
    Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2:e78.
  • 8
    Verhagen J, Blaser K, Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Immunol Allergy Clin North Am 2006;26:207231.
  • 9
    Ferreira FD, Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C, Sommergruber W, et al. Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I. J Biol Chem 1993;268:1957419580.
  • 10
    Wiedermann U, Jahn-Schmid B, Fritsch R, Bauer L, Renz H, Kraft D, et al. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. Clin Exp Immunol 1998;111:144151.
  • 11
    Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 2005;35:15111520.
  • 12
    Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129134.
  • 13
    Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:18691871.
  • 14
    Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389395.
  • 15
    Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003;22:8795.
  • 16
    Shida K, Takahashi R, Iwadate E, Takamizawa K, Yasui H, Sato T, et al. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy 2002;32:563570.
  • 17
    Ohno H, Tsunemine S, Isa Y, Shimakawa M, Yamamura H. Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull 2005;28:14621466.
  • 18
    Crameri R, Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006;18:761768.
  • 19
    Kruisselbrink A, Heijne Den Bak-Glashouwer MJ, Havenith CE, Thole JE, Janssen R. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T- cell responses. Clin Exp Immunol 2001;126:28.
  • 20
    Van De Guchte M, Van Der Vossen JM, Kok J, Venema G. Construction of a lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. Appl Environ Microbiol 1989;55:224228.
  • 21
    Daniel C, Repa A, Wild C, Pollak A, Pot B, Breiteneder H, et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 2006;61:812819.
  • 22
    Ferain T, Garmyn D, Bernard N, Hols P, Delcour J. Lactobacillus plantarum ldhL gene: overexpression and deletion. J Bacteriol 1994;176:596601.
  • 23
    Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 2000;14:823828.
  • 24
    Grangette C, Muller-Alouf H, Geoffroy M, Goudercourt D, Turneer M, Mercenier A. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 2002;20:33043309.
  • 25
    Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P, et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005;35:539546.
  • 26
    Chatel JM, Nouaille S, Adel-Patient K, Le Loir Y, Boe H, Gruss A, et al. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol 2003;69:66206627.
  • 27
    Scheppler L, Vogel M, Marti P, Muller L, Miescher SM, Stadler BM. Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease. Vaccine 2005;23:11261134.
  • 28
    Charng YC, Lin CC, Hsu CH. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria. Vaccine 2006;24:59315936.